Similar articles

• Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.

  Guarneri L, Angelico P, Ibba M, Poggesi E, Taddei C, Leonardi A, Testa R. Guarneri L, et al. Arzneimittelforschung. 1996 Jan;46(1):15-24. Arzneimittelforschung. 1996. PMID: 8821512
• Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties.

  Hu H, Marban E. Hu H, et al. Mol Pharmacol. 1998 May;53(5):902-7. Mol Pharmacol. 1998. PMID: 9584217
• [New findings on calcium antagonism].

  Ferrari R, Ceconi C, Curello S, Visioli O. Ferrari R, et al. Ann Ital Med Int. 1992 Jul-Sep;7(3 Suppl):100S-111S. Ann Ital Med Int. 1992. PMID: 1338419 Review. Italian.
• Inhibition of voltage-gated L-type calcium channels by labedipinedilol-A involves protein kinase C in rat cerebrovascular smooth muscle cells.

  Wu BN, Chen ML, Dai ZK, Lin YL, Yeh JL, Wu JR, Chen IJ. Wu BN, et al. Vascul Pharmacol. 2009 Aug-Sep;51(2-3):65-71. doi: 10.1016/j.vph.2009.03.001. Epub 2009 Mar 17. Vascul Pharmacol. 2009. PMID: 19298869
• Factors modifying the tissue selectivity of calcium-antagonists.

  Spedding M, Fraser S, Clarke B, Patmore L. Spedding M, et al. J Neural Transm Suppl. 1990;31:5-16. J Neural Transm Suppl. 1990. PMID: 1963634 Review.